Latest filing published 29 Sept 2026 for Definium Therapeutics, Inc., €349k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Daniel Karlin in Definium Therapeutics, Inc. In total, 12 filings cover trades dated from 12 March 2025 to 25 September 2026.
No open-market purchase appears, only 7 sales worth €1.1M. The rest of the record consists of 5 share grants. Since January 2026: no purchases and 3 sales on the market.
Most recently, on 29 September 2026, the filings show an open-market sale worth €349k in Definium Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
12 of 12 declarations